SCHEMBL15050792

SCHEMBL15050792

CNC(C)C(=O)NC(C(=O)N1CCCC1C(=O)Nc1cc2c(Nc3ccccc3OC)ncnc2cc1OC)C(C)(C)C

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.80
XIAP P98170 4/20 0.80
CYP2C9 P11712 2/20 0.80
CYP2C19 P33261 1/20 0.80
EGFR P00533 5/20 0.47
ERBB2 P04626 4/20 0.47
KDR P35968 3/20 0.47
RAF1 P04049 2/20 0.47
FGFR2 P21802 2/20 0.47
FLT4 P35916 2/20 0.47
TEK Q02763 2/20 0.47
ABL1 P00519 1/20 0.47
LCK P06239 1/20 0.47
RET P07949 1/20 0.47
SRC P12931 1/20 0.47
BIRC2 Q13490 5/20 0.45
BIRC3 Q13489 1/20 0.45
FLT1 P17948 1/20 0.45
RIPK2 O43353 1/20 0.41
JAK3 P52333 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15050790 1.00 CYP3A4 (0.80) CYP3A4XIAPCYP2C9CYP2C19EGFR
Hydrochloric Acid SCHEMBL15050319 0.99 CYP3A4 (0.79) CYP3A4XIAPCYP2C9CYP2C19EGFR
Hydrochloric Acid SCHEMBL15050320 0.99 CYP3A4 (0.79) CYP3A4XIAPCYP2C9CYP2C19EGFR
SCHEMBL15050573 0.95 CYP3A4 (0.78) CYP3A4XIAPCYP2C9CYP2C19EGFR
SCHEMBL15050570 0.95 CYP3A4 (0.78) CYP3A4XIAPCYP2C9CYP2C19EGFR
SCHEMBL15051214 0.94 CYP3A4 (0.79) CYP3A4XIAPCYP2C9CYP2C19EGFR
Hydrochloric Acid SCHEMBL15050075 0.94 CYP3A4 (0.77) CYP3A4XIAPCYP2C9CYP2C19EGFR
SCHEMBL15050173 0.94 CYP3A4 (0.77) CYP3A4XIAPCYP2C9CYP2C19EGFR
SCHEMBL15050732 0.94 CYP3A4 (0.77) CYP3A4XIAPCYP2C9CYP2C19EGFR
SCHEMBL15050176 0.94 CYP3A4 (0.77) CYP3A4XIAPCYP2C9CYP2C19EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611797-B1 QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS HANMI SCIENCE CO LTD (KR) 2016-12-28 EP claimed
US-8835458-B2 Quinoline or quinazoline derivatives with apoptosis inducing activity on cells HANMI SCIENCE CO., LTD (KR) 2014-09-16 US claimed
US-20130165386-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS HANMI SCIENCE CO., LTD (KR) 2013-06-27 US claimed
EP-2611797-B1 QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS HANMI SCIENCE CO LTD (KR) 2016-12-28 EP disclosed
US-8835458-B2 Quinoline or quinazoline derivatives with apoptosis inducing activity on cells HANMI SCIENCE CO., LTD (KR) 2014-09-16 US disclosed
US-20130165386-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS HANMI SCIENCE CO., LTD (KR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165386-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS CASP7, API5, BAX CYP3A4 2789/4885XIAP 24/4885CYP2C9 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.